These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21442382)

  • 21. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
    Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S
    Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.
    Jacobs L; Samson MM; Verhaar HJ; Koek HL
    Neth J Med; 2012 Jan; 70(1):35-8. PubMed ID: 22271812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
    Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
    Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cinacalcet in the management of primary hyperparathyroidism.
    Cetani F; Marcocci C
    Expert Rev Endocrinol Metab; 2012 Jan; 7(1):45-53. PubMed ID: 30736110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
    Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
    Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics].
    Brardi S; Ponchietti R; Duranti E
    G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study.
    Brardi S; Cevenini G; Verdacchi T; Romano G; Ponchietti R
    Arch Ital Urol Androl; 2015 Mar; 87(1):66-71. PubMed ID: 25847900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
    Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
    Manaka K; Sato J; Kinoshita Y; Ito N; Fujita M; Iiri T; Nangaku M; Makita N
    Endocr J; 2019 Aug; 66(8):683-689. PubMed ID: 31092749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
    Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
    J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ye Z; Silverberg SJ; Sreekanta A; Tong K; Wang Y; Chang Y; Zhang M; Guyatt G; Tangamornsuksun W; Zhang Y; Manja V; Bakaa L; Couban RJ; Brandi ML; Clarke B; Khan AA; Mannstadt M; Bilezikian JP
    J Bone Miner Res; 2022 Nov; 37(11):2351-2372. PubMed ID: 36053960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet for the treatment of primary hyperparathyroidism.
    Sajid-Crockett S; Singer FR; Hershman JM
    Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
    Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism.
    Wilhelm-Bals A; Parvex P; Magdelaine C; Girardin E
    Pediatrics; 2012 Mar; 129(3):e812-6. PubMed ID: 22331334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
    Henrich LM; Rogol AD; D'Amour P; Levine MA; Hanks JB; Bruns DE
    Clin Chem; 2006 Dec; 52(12):2286-93. PubMed ID: 17105782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
    Shoback DM; Bilezikian JP; Turner SA; McCary LC; Guo MD; Peacock M
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5644-9. PubMed ID: 14671147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.